DIAGNOS has named Lloyd M. Segal and Michael Singer as directors of the corporation. Segal is a managing partner at Persistence Capital Partners while Singer is a former chairman of the board of directors at Warnex. Headquartered in Quebec, DIAGNOS is a provider of healthcare technical services.
BROSSARD, QUEBEC–(Marketwired – July 24, 2014) – DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis and image processing, is pleased to announce the appointment of Mr. Lloyd M. Segal and Mr. Michael Singer as Directors of the Corporation following the resignations of Mr. Rich Baxter and Mr. Bruno Maruzzo.
The Board wishes to thank Mr. Baxter and Mr. Maruzzo for their important contribution to DIAGNOS.
Mr. Segal is Managing Partner at Persistence Capital Partners (“PCP”), Canada’s only private equity fund exclusively focused on high-growth opportunities in Canadian healthcare. Mr. Segal is responsible for all aspects of PCP’s investments from sourcing, evaluating and executing on investment opportunities, to managing existing investments. Mr. Segal has previously served as a director of several public and private corporations in the U.S. and Canada.
Mr. Singer is a Pharmaceutical industry Chief Financial Officer and consultant with senior level experience in both public and private life science and innovative technology companies. Prior to joining DIAGNOS, Mr. Singer served as Chairman of the board of Directors of Warnex Inc. (“Warnex”). On July 8th, 2014, Warnex was amalgamated with a wholly-owned subsidiary of DIAGNOS.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.